Clinical Trials

Circulating MrgD in Pulmonary Hypertension

Study Purpose

The aim of the study is to observe the change of the circulating MrgD level in patients with pulmonary hypertension compared with subjects without pulmonary hypertension.

Recruitment Criteria

Accepts Healthy Volunteers Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms	Yes
Study Type An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies.	Observational
Eligible Ages	18 Years and Over
Gender	All

More Inclusion & Exclusion Criteria

Inclusion criteria for patients with pulmonary hypertension： 1. Male or female aged ≥18 years. 2. Right heart catheterisation to check the mean pulmonary artery pressure (mPAP) ≥25mmHg. 3. The patient is willing and able to provide written informed consent. Exclusion criteria for patients with pulmonary hypertension： 1. Age less than 18 years old. 2. Mean pulmonary artery pressure (mPAP) <25mmHg. 3. Unable to provide informed written consent for participation in the study. 4. Renal insufficiency. 5. Liver insufficiency. 6. Malignant tumor. 7. Active infection. 8. Pregnancy. Inclusion criteria for control subjects： 1. Male or female aged ≥18 years. 2. No evidence of pulmonary hypertension on echocardiography or mean pulmonary artery pressure (mPAP) < 25 mmHg on right heart catheterization, and no evidence of clinically relevant heart disease. 3. No evidence of clinically relevant pulmonary disease. Exclusion criteria for control subjects： 1. Age less than 18 years old. 2. Mean pulmonary artery pressure (mPAP) ≥25mmHg. 3. Unable to provide informed written consent for participation in the study. 4. Symptoms of heart failure or clinically relevant lung disease. 5. Renal insufficiency. 6. Liver insufficiency. 7. Malignant tumor. 8. Active infection. 9. Pregnancy

Trial Details

Trial ID: This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.	NCT06365372
Phase Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.
Lead Sponsor The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.	Qilu Hospital of Shandong University
Principal Investigator The person who is responsible for the scientific and technical direction of the entire clinical study.	N/A
Principal Investigator Affiliation	N/A
Agency Class Category of organization(s) involved as sponsor (and collaborator) supporting the trial.	Other
Overall Status	Recruiting
Countries	China
Conditions The disease, disorder, syndrome, illness, or injury that is being studied.	Pulmonary Hypertension

Arms & Interventions

Arms

: PAH

: Non-PAH

Interventions

Diagnostic Test: - Western blot

Samples were measured by Western blot using a solution for the separation of lymphocytes from peripheral blood.

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.